Lung Cancer News and Research

Latest Lung Cancer News and Research

BHGI's approach to cancer treatment guidelines for low- and moderate-income countries

When the prestigious British medical journal The Lancet Oncology this week published six cancer treatment guideline papers aimed at the resource-diverse nations of Asia, it used as its model the economic template developed by the Breast Health Global Initiative (BHGI) based at Fred Hutchinson Cancer Research Center.

31 Oct 2009

Eisai reports global Phase III study results of eribulin mesylate

Eisai Inc. today announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic breast cancer.

30 Oct 2009

ASTRO to host news briefings on top cancer research papers

The American Society for Radiation Oncology (ASTRO) will host four news briefings with accompanying live webcasts on the top cancer research papers from its 51st Annual Meeting.

30 Oct 2009

Fiscal 2009 results announced by Helix BioPharma

Helix BioPharma Corp. today announced financial results for the year ended July 31, 2009.

30 Oct 2009

Researchers use BEZ235 drug to eliminate NSCL cancer

Researchers at UT Southwestern Medical Center have eliminated non-small cell lung (NSCL) cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation.

30 Oct 2009

Celera to use Medical Therapies' midkine patent portfolio for development of novel lung cancer diagnostics

Celera Corporation, a health care company focused on genetics, and Medical Therapies Limited (ASX:MTY), a biotechnology company developing midkine-related diagnostic and therapeutic products, have entered into an exclusive license agreement for the use of MTY’s midkine patent portfolio for the development of novel lung cancer diagnostics.

30 Oct 2009

World’s first Cesium-131 lung implants performed

IsoRay, Inc. announced today that starting on August 12, 2009, Dr. Bhupesh Parashar from the Department of Radiation Oncology, and Dr. Nasser Altorki of the Department of Cardiothoracic Surgery at Weill Cornell Medical Center performed the world’s first Cesium-131 lung implants.

29 Oct 2009

Highlights of new cancer research to be presented at 51st ASTRO Annual Meeting

The following are highlights of new cancer research being presented at the American Society for Radiation Oncology's (ASTRO) 51st Annual Meeting on November 1-5, 2009, in Chicago.

29 Oct 2009

Biomoda to launch multisite Phase III clinical trials of CyPath assay

Medical diagnostics company Biomoda, Inc. is taking preliminary steps to launch multisite Phase III clinical trials of its in-vitro diagnostic for early-stage lung cancer, trademarked under the name CyPath®.

29 Oct 2009

U.S. PTO awards Endocyte patent for vitamin receptor binding anti-cancer agents

Officials at Endocyte Inc., a cancer drug discovery and development company, announced Tuesday (Oct. 27, 2009) that the company has been awarded a patent from the U.S. Patent and Trademark Office covering vitamin receptor binding anti-cancer agents.

28 Oct 2009

Bcl-2 inhibitor may enhance chemotherapy treatment in patients with prostate cancer

In trying to better predict a patient's response to chemotherapy for cancer treatment, a team of investigators at The Cancer Institute of New Jersey (CINJ) and Rutgers, The State University of New Jersey, has identified a way to better manipulate a gene product to cause cancer cells to die.

28 Oct 2009

Hope for lung cancer patients

Lung cancer is the world's most common cancer, and an estimated 219,440 Americans are expected to be diagnosed this year. It is also estimated that lung cancer will cause 159,000 deaths in the United States this year - more than the total number of deaths resulting from breast, colon and prostate cancers combined.

27 Oct 2009

ImmunoCellular Therapeutics presents additional data from its ICT-107 Phase I clinical trial

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is focused on the development of novel immune-based cancer therapies, today announced additional data from its Phase I clinical trial evaluating ICT-107, the Company’s dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme (GBM).

27 Oct 2009

Astellas enters into agreement with Medivation to develop MDV3100

Astellas Pharma Inc. ("Astellas") and Medivation, Inc. announced today that they have entered into a global agreement to develop and commercialize MDV3100, Medivation's investigational drug for the treatment of prostate cancer.

27 Oct 2009

BioMarin Pharmaceutical announces the acquisition of Huxley Pharmaceuticals

BioMarin Pharmaceutical Inc. announced today that it has acquired Huxley Pharmaceuticals, Inc. (Huxley), which has rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).

27 Oct 2009

ImmunoCellular Therapeutics to present Phase I clinical trial data of ICT-107 vaccine in New Orleans

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, today announced that it will be presenting today, at the Annual Meeting of the Congress of Neurological Surgeons in New Orleans, Louisiana at 3:15pm central time, data from its Phase I clinical trial investigating the role that its ICT-107 vaccine may play in increasing patient survival and inhibiting tumor progression in patients with glioblastoma, the most common and most aggressive type of primary brain tumor.

26 Oct 2009

Ontario Lung Association partners with Health Canada for radon gas awareness campaign

As winter weather approaches and we move activities indoors, it's a good time to think about the quality of the air in our homes. Radon is a colourless, odourless gas that is produced from the natural breakdown of uranium in rocks and soil. Radon can enter a home through tiny openings in floors and foundations and build up to dangerous levels. Long-term exposure to radon is the second leading cause of lung cancer in Canada.

26 Oct 2009

Biomoda to complete Phase II clinical trial of Biomoda assay for lung cancer detection

Biomoda, Inc., a diagnostics company focused on the development of accurate, inexpensive and noninvasive in-vitro tests for the early detection of cancer, has met its recruitment goal for New Mexico veterans with a history of heavy smoking required to complete the Phase II clinical trial of Biomoda's early-stage diagnostic for lung cancer.

24 Oct 2009

Michelle Obama to speak to the American women on Health Care Reform through a video

First Lady Michelle Obama will be speaking to the women of America about Health Care Reform through a video produced by the White House, which will break exclusively on www.iVillage.com at 7:00 am on Friday, October 23rd at http://www.ivillage.com/michelleobama.

24 Oct 2009

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in an international Phase 3 trial to evaluate Nexavar® (sorafenib) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer.

23 Oct 2009

Lung Cancer News and Research

Latest Lung Cancer News and Research

BHGI's approach to cancer treatment guidelines for low- and moderate-income countries

Eisai reports global Phase III study results of eribulin mesylate

ASTRO to host news briefings on top cancer research papers

Fiscal 2009 results announced by Helix BioPharma

Researchers use BEZ235 drug to eliminate NSCL cancer

Celera to use Medical Therapies' midkine patent portfolio for development of novel lung cancer diagnostics

World’s first Cesium-131 lung implants performed

Highlights of new cancer research to be presented at 51st ASTRO Annual Meeting

Biomoda to launch multisite Phase III clinical trials of CyPath assay

U.S. PTO awards Endocyte patent for vitamin receptor binding anti-cancer agents

Bcl-2 inhibitor may enhance chemotherapy treatment in patients with prostate cancer

Hope for lung cancer patients

ImmunoCellular Therapeutics presents additional data from its ICT-107 Phase I clinical trial

Astellas enters into agreement with Medivation to develop MDV3100

BioMarin Pharmaceutical announces the acquisition of Huxley Pharmaceuticals

ImmunoCellular Therapeutics to present Phase I clinical trial data of ICT-107 vaccine in New Orleans

Ontario Lung Association partners with Health Canada for radon gas awareness campaign

Biomoda to complete Phase II clinical trial of Biomoda assay for lung cancer detection

Michelle Obama to speak to the American women on Health Care Reform through a video

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Lung Cancer News and Research

Latest Lung Cancer News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in